SUNNYVALE, Calif., Jan. 26, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2011 of $80.1 million. Net loss was $1.6 million, or $(0.03) per share, which compares to revenue of $58.7 million and net income of $1.3 million, or $0.02 per diluted share, in the fourth quarter of 2010. As anticipated, the fourth quarter net loss reflected a one-time, non-cash charge to cost of sales of $5.4 million, or $0.08 per share, associated with the termination of a patent license.
Excluding stock compensation expenses, the non-cash charge of $5.4 million associated with the termination of a patent license, and amortization of acquired intangibles, non-GAAP net income for the fourth quarter of 2011 was $9.4 million, or $0.14 per share. This compares to a non-GAAP net income of $6.1 million, or $0.09 per share, in the fourth quarter of 2010.
Fiscal 2011 OverviewFor the year ended December 31, 2011, Cepheid reported revenue of $277.6 million which compares to revenue of $212.5 million in 2010. Net income for the year was $2.6 million, or $0.04 per diluted share, which compares to a net loss of $5.9 million, or $(0.10) per share, in 2010. Excluding stock compensation expenses, the non-cash charge of $5.4 million associated with the termination of a patent license, and amortization of acquired intangibles, non-GAAP net income for the year was $29.6 million, or $0.44 per share. This compares to a non-GAAP net income of $12.5 million, or $0.20 per share, for the full year 2010.
"GeneXpert system placements continued at a very strong pace in the fourth quarter contributing to a record number of placements during 2011, in both our commercial and High Burden Developing Country programs," said John Bishop, Cepheid's Chief Executive Officer. "The demand for our GeneXpert systems has continued to grow in spite of continuing tight capital availability in the US and Europe. In 2012, we will continue to invest aggressively in Xpert® test menu expansion to enable the benefits of our system to be realized in broader segments of the market. We expect to further extend our technology leadership and strong growth momentum in the quarters and years ahead."
Three Months Ended December 31,Full Year Ended December 31,20112010Change20112010ChangeClinical Systems
49.036.833%177.4131.335%Total Clinical 68.949.539%236.0173.836%Non-Clinical
8.06.719%29.533.1-11%Total Product Sales$
7.25.433%25.027.3-8%Total North America53.643.922%192.9164.617%InternationalClinical
0.81.3-38%4.55.8-22%Total International23.312.389%72.642.372%Total Product Sales$
Business OutlookFor the fiscal year ending December 31, 2012, the Company expects:
Expected non-GAAP net income excludes approximately $26 million related to stock compensation expense, approximately $2 million related to the amortization of acquired intangibles, and up to a $1.9 million non-cash tax benefit relating to a potential change to our international tax and legal entity structure. The fully diluted share count for the year is expected to be between 70 and 71 million.
Accessing Cepheid's Fourth Quarter and Full Year 2011 Results Conference CallThe Company will host a management presentation at 2:00 p.m. Pacific Time on Thursday, January 26, 2012, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.
Interested participants and investors may also listen to the live teleconference call by dialing (866) 713-8395 or (617) 597-5309, and entering participant code 42214013. A replay will be available for seven days beginning at 4:00 p.m. Pacific Time. Access numbers for this replay are (888) 286-8010 or (617) 801-6888, with passcode 57636855.
About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
Use of Non-GAAP MeasuresThe Company has supplemented its reported GAAP financial information with non-GAAP measures that do not include employee share-based compensation expense, a non-cash charge associated with the termination of a patent license and amortization of purchased intangible assets. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with U.S. GAAP. The Company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the Company's cash requirements and additional insight into the underlying operating results and the Company's ongoing performance in the ordinary course of its operations.
These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with U.S. GAAP and that these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.
As described above, the Company excludes the following items from one or more of its non-GAAP measures when applicable:
Employee stock-based compensation expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under ASC 718 (formerly SFAS 123(R)). The Company excludes employee stock-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results in the period incurred. Further, as the Company applies ASC 718, it believes that it is useful to investors to understand the impact of the application of ASC 718 on its results of operations.
Termination of License. The Company incurred a one-time expense of $5.4 million in the fourth quarter of 2011 related to the acceleration of the remaining amortization of the original up-front license fee related to the Roche license. The Company excludes this item because it is one-time and non-cash in nature and not reflective of ongoing operating results in the period incurred.
Amortization of purchased intangible assets. The Company incurs amortization of purchased intangible assets in connection with acquisitions. The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred. These amounts arise from the Company's prior acquisitions and have no direct correlation to the operation of the Company's business.
Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth, future revenues and future net income/loss, including on a non-GAAP basis, and test menu expansion. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program; unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.FINANCIAL TABLES FOLLOWCEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended December 31, Years Ended December 31, 2011201020112010Revenues:System sales
46,416Reagent and disposable sales
56,57642,969203,576160,460Total product sales
80,11458,726277,575212,468Costs and operating expenses:Cost of product sales
38,63226,570122,840105,135Collaboration profit sharing
1,5821,0934,8636,806Research and development
16,65011,66659,36242,503Sales and marketing
14,49010,62650,69138,840General and administrative
10,1536,93236,00424,528Total costs and operating expenses
81,50756,887273,760217,812Income (loss) from operations
(1,393)1,8393,815(5,344)Other expense, net
(506)(346)(1,143)(992)Income (loss) before income taxes
(1,899)1,4932,672(6,336)Benefit from (provision for) income taxes
250(148)(45)419Net income (loss)
(5,917)Basic net income (loss) per share
(0.10)Diluted net income (loss) per share
(0.10)Shares used in computing basic net income (loss) per share
64,11360,41362,73559,712Shares used in computing diluted net income (loss) per share
64,11363,37266,75059,712CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)December 31, 2011December 31, 2010ASSETSCurrent assets:Cash and cash equivalents
79,538Accounts receivable, net
62,23937,598Prepaid expenses and other current assets
5,2454,138Total current assets
217,867149,284Property and equipment, net
35,83327,438Other non-current assets
730607Intangible assets, net
220,611LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable
8,3577,994Accrued and other liabilities
3,0861,288Current portion of deferred revenue
8,1768,207Current portion of notes payable
-1,679Total current liabilities
69,71453,719Long-term portion of deferred revenue
2,0034,057Notes payable, less current portion
74,83766,949Shareholders' equity:Common stock
324,211288,387Additional paid-in capital
93,14472,731Accumulated other comprehensive income
(205,555)(208,182)Total shareholders' equity
211,833153,662Total liabilities and shareholders' equity
220,611CEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS(in thousands)Years Ended December 31,20112010Cash flows from operating activities:Net income (loss)
(5,917)Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization of property and equipment
10,2989,326Amortization of intangible assets
6,5236,966Amortization of terminated patent license
5,372-Stock-based compensation related to employees and consulting services rendered
19,76816,615Write-offs of other intangible assets acquired in acquisitions
-271Unrealized gain on auction rate securities
-(1,714)Unrealized loss on put option
1885Changes in operating assets and liabilities:Accounts receivable
(23,982)124Prepaid expenses and other current assets
(237)(1,426)Other non-current assets
(122)(113)Accounts payable and other current liabilities
(2,084)7,062Net cash provided by operating activities
27,03227,343Cash flows from investing activities:Capital expenditures
(18,942)(13,047)Acquisition of leasehold improvements
-125Payments for technology licenses
(1,655)(1,000)Cost of acquisitions, net
(296)(1,300)Proceeds from the sales of short-term investments
-24,800Proceeds from the sale of fixed assets
20138Net cash provided by (used in) investing activities
(20,873)9,716Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options
35,85715,334Proceeds from notes payable
-6,448Principal payment of bank borrowing
-(14,618)Principal payment of notes payable
(6,669)(618)Net cash provided by financing activities
29,1886,546Effect of exchange rate change on cash
123147Net increase in cash and cash equivalents
35,47043,752Cash and cash equivalents at beginning of period
79,53835,786Cash and cash equivalents at end of period
79,538CEPHEIDRECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months Ended
December 31,Years Ended
December 31,2011201020112010Cost of product sales$
5,135 Stock compensation expense(443)(687)(1,684)(2,522) Amortization of terminated patent license(5,372)-(5,372)- Amortization of purchased intangible assets(347)(394)(1,383)(1,422)Non-GAAP measure of cost of product sales$
,191Gross margin on product sales per GAAP50%53%54%49%Gross margin on product sales per Non-GAAP58%55%57%51%Operating expenses$
5,871 Stock compensation expense(4,806)(3,614)(18,084)(14,093) Amortization of purchased intangible assets(107)(78)(429)(409)Non-GAAP measure of operating expenses$
91,369Income (loss) from operations$
(5,344) Stock compensation expense5,2494,30119,76816,615 Amortization of terminated patent license5,372-5,372- Amortization of purchased intangible assets4544721,8121,831Non-GAAP measure of income from operations$
3,102Net income (loss)$
(5,917) Stock compensation expense5,2494,30119,76816,615 Amortization of terminated patent license5,372-5,372- Amortization of purchased intangible assets4544721,8121,831Non-GAAP measure of net income$
2,529Basic net income (loss) per share$
(0.10) Stock compensation expense0.080.070.320.28 Amortization of terminated patent license0.09-0.08- Amortization of purchased intangible assets0.010.010.030.03Non-GAAP measure of net income per share$
.21Diluted net income (loss) per share$
(0.10) Stock compensation expense0.080.060.290.27 Amortization of terminated patent license0.08-0.08- Amortization of purchased intangible assets0.010.010.030.03Non-GAAP measure of net income per share$
.20Shares used in computing Non-GAAP basic net income (loss) per share64,11360,41362,73559,712Shares used in computing diluted net income per share64,11363,37266,75059,712Incremental shares from the assumed conversion of dilutive stock options4,4801,3678783,875Shares used in computing Non-GAAP diluted net income per share68,59364,73967,62863,587CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton
Cepheid Corporate Communications
Tel: (408) 400 8377
Cepheid Investor Relations
Tel: (408) 400 8329
Copyright©2010 PR Newswire.
All rights reserved